Very large scale monoclonal antibody purification: The case for conventional unit operations

Biotechnology Progress

Volumn 23, Issue 5, 2007, Pages 995-1008

  Kelley, Brian ^a,b  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MEMBRANES; BIOTECHNOLOGY; CHROMATOGRAPHY; PROTEINS; PURIFICATION; ULTRAFILTRATION;

PROCESS CHROMATOGRAPHY; PROTEIN THERAPEUTICS;

MONOCLONAL ANTIBODIES;

MONOCLONAL ANTIBODY;

CHROMATOGRAPHY; COST; ECONOMICS; FRACTIONATION; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; METHODOLOGY; REVIEW; STATISTICAL MODEL;

ANTIBODIES, MONOCLONAL; CHEMICAL FRACTIONATION; CHROMATOGRAPHY; COSTS AND COST ANALYSIS; INTERNATIONALITY; MODELS, ECONOMIC;

EID: 35348866110     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp070117s     Document Type: Review

References (33)

1. Jagschies, G.; Grönberg, A.; Björkman, T.; Lacki, K.; Johansson, H. J. Technical and economical evaluation of downstream processing options for monoclonal antibody (MAb) Production. Suppl. BioPharm Int. 2006, Jun 2.
2. Luan, Y-T.; Wang, W.; Nolan, R.; Drapeau, D. Defined Medium Development for High Yielding Mammalian Cell Culture Processes. IBC & Bioprocess International Conference; 8 November, 2006; San Francisco, CA.
3. Low, D; O'Leary, R.; Pujar, N. S. Future of antibody purification. J. Chromatogr. B 2007, 848, 48-63.
4. Curling, J.; Bryant, C. The plasma fractionation industry new opportunities to move forward? BioProcess Int. 2005, 3 (3), 10-16.
5. Smith, E. M. Chromatographic Albumin Production-Pilot to Production. Downstream 2000, 31, 6-8.
6. Johnston, A.; Adcock, W. The Use of Chromatograph to manufacture purer and safer plasma products. Biotechnol. Gen. Eng. Rev. 2000, 17, 37-70.
7. Martin, T. IGIV: Contents, properties, and methods of industrial production-evolving closer to a more physiologic product. Int. Immunopharmacol. 2006, 6, 517-522.
8. Curling, J. Affinity chromatography-From textile dyes to synthetic ligands by design. BioPharm 2004, 17 (7), 34-42.
9. Ladisch, M. R.; Kohlmann, K. L. Recombinant human insulin. Biotechnol. Prog. 1992, 8, 469-478.
10. Li, F.; Zhou, J. X.; Yang, X.; Tressel, T.; Lee, B. Current therapeutic antibody production and process optimization. Bioprocess. J. 2005, Sep/Oct, 23-30.
11. Shukla, A.; Hubbard, B.; Tressel, T.; Guhan, S.; Low, D. Downstream processing of monoclonal antibodies-Application of platform approaches. J. Chromatogr. B 2007, 848, 28-39.
12. Kempken, R.; Preissmann, A.; Berthold, W. Assessment of a disc stack centrifuge for use in mammalian cell separation. Biotechnol. Bioeng. 1995, 46, 132-138.
13. Bender, J.; Wolk, B. Putting a Spin on CHO harvest: Centrifuge technology development, National Meeting of the American Chemical Society, Boston, MA, August, 1998; American Chemical Society: Washington DC, 1998.
14. Hahn, R.; Schlegel, R.; Jungbauer, A. Comparison of Protein A affinity sorbents. J. Chromatogr. 2003, 790, 35-51.
15. Swinnen, K.; Krul, A.; Van Goidsenhoven, I.; Van Tichelt, N.; Roosen, A.; Van Houdt, K. Performance comparison of Protein A affinity resins for the purification of monoclonal antibodies. J. Chromatogr. B 2007, 848, 97-107.
16. Brorson, K.; Krejci, S.; Lee, K.; Hamilton, E.; Stein, K.; Xu, Y. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng. 2003, 82, 321-329.
17. Kelley, B.; Tobler, S. A.; Brown, P.; Coffman, J.; Godavarti, R.; Iskra, T.; Switzer, M.; Vunnum, S. Principles of weak partitioning chromatography for anion exchange purification of monoclonal antibodies. Biotechnol. Bioeng. 2007, submitted for publication.
18. Fahrner, R. L.; Knudsen, H. L.; Basey, C. D.; Galan, W.; Feuerhelm, D.; Vanderlaan, M.; Blank, G. S. Industrial purification of pharmaceutical antibodies: Development, operation, and validation of chromatography processes. Biotechnol. Genet. Eng. Rev. 2001, 18, 301-327.
19. Carter, J.; Lutz, H. An overview of viral filtration in biopharmaceutical manufacturing. Eur. J. Parenter. Sci. 2002, 7 (3), 72-78.
20. Phillips, MW; Bolton, G; Krishnan, M; Lewnard, JJ; Raghunath, B. Virus filtration process design and implementation. In Process Scale Bioseparations for the Biopharmaceutical Industry; Shukla, A. A., Etzel, M. R., Gadam, S., Eds.; Taylor & Francis: Boca Raton, 2007; pp 333-365.
21. Bolton, G.; Cabatingan, M.; Rubino, M.; Lute, S.; Brorson, K.; Bailey, M. Normal-flow virus filtration: Detection and assessment of the endpoint in bioprocessing. Biotechnol. Appl. Biochem. 2005, 42, 133-142.
22. Hongo-Hirasaki, T; Yamaguchi, K; Yanagida, K; Okuyama, K. Removal of small viruses (parvovirus) from IgG solution by virus removal filter Planova®20N. J. Membr. Sci. 2006, 278, 3-9.
23. Williams, A.; Taylor, K.; Dambuleff, K.; Persson, O.; Kennedy, R. M. Maintenance of column performance at scale. J. Chromatogr. A 2002, 44, 69-75.
24. Scaled-up Method for Packing MabSelect in Large Diameter Chromaflow Columns; Technical Brief 11-0007-52 B; Amersham BioSciences (now GE Healthcare): Uppsala, Sweden, 2004; 2004-09.
25. Kelley, B. D. Establishing process robustness through designed experiments. In Biopharmaceutical Process Validation; Zabriske, D., Sofer, G., Eds.; Marcel Dekker: New York, 2000; pp 29-59.
26. Brorson, K.; Brown, J.; Hamilton, E.; Stein, K. E. Identification of Protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J. Chromatogr. A 2003, 989, 155-163.
27. Farid, S. S. Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B 2007, 848 (8-18).
28. Chadd, H. E.; Chamow, S. M. Therapeutic antibody expression technology. Curr. Opin. Biotechnol. 2001, 12, 188-194.
29. Clearer Paradigm Sought For Biopharmaceutical Specifications, Gold Sheet 2004, 38 (2).
30. Farrugia, A.; Robert, P. Plasma protein therapies: current and future perspectives. Best Pract. Res. Clin. Haematol. 2006, 19, 243-58.
31. Blank, G. S. Design and Scale-up of a Monoclonal Antibody Recovery Process. Recovery of Biological Products X; 7 June, 2001; Cancun, Mexico.
32. Madani, H. Enbrel Product Lifecycle from Phase I to Market Lauch and Beyond. Recovery of Biological Products XI; 18 September, 2003; Banff, Canada.
33. Shpritzer, R.; Vicik, S.; Orlando, S.; Acharya, H.; Coffman, J. L. Calcium phosphate flocculation of antibody-producing mammalian cells at pilot scale. Abstracts of Papers, 232nd National Meeting of the American Chemical Society, San Francisco, CA, Sept 10-14, 2006; American Chemical Society: Washington, DC, 2006; BIOT-080.